

TOXICOLOGICAL PROFILE FOR TOXAPHENE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

October 2014

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

UPDATE STATEMENT

A Toxicological Profile for Toxaphene, Draft for Public Comment was released in September 2010. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road NE
Mailstop F-57
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Robin M. Ikeda, M.D., M.P.H.
Acting Assistant Administrator
Agency for Toxic Substances and Disease Registry

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Chapter 1	How Can (Chemical X) Affect Children?
Chapter 1	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)

Internet: <http://www.atsdr.cdc.gov>

The following additional material is available online at www.atsdr.cdc.gov:

Case Studies in Environmental Medicine—Case Studies are self-instructional publications designed to increase primary care provider's knowledge of a hazardous substance in the environment and to aid in the evaluation of potentially exposed patients.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, Patriots Plaza Building, Washington, DC 20201 • Phone: (202) 245-0625 or 1-800-CDC-INFO (800-232-4636).

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Clinical Resources

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Nickolette Roney, MPH
LT Jona M. Ogden, MPH, U.S. Public Health Service
CDR Robert L. Williams, Ph.D., U.S. Public Health Service
Yulia Iossifova, MD, Ph.D.
Malcolm Williams, DVM, Ph.D.
John R. Doyle, MPA
ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

David Wohlers, Ph.D.
Courtney Hard, B.S.
Daniel Plewak, B.S.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for toxaphene. The panel consisted of the following members:

1. Dr. Laurie H.M. Chan, Professor, Aboriginal Environmental Health, University of Northern British Columbia, Prince George BC V2N 4Z9, Canada;
2. Dr. Lucio G. Costa, Professor, Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington; and
3. Dr. Mark Robson, Professor and Dean of Agricultural and Urban Programs, Rutgers University, New Brunswick, New Jersey.

These experts collectively have knowledge of toxaphene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS.....	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT FOR TOXAPHENE.....	1
2. RELEVANCE TO PUBLIC HEALTH	9
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TOXAPHENE IN THE UNITED STATES	9
2.2 SUMMARY OF HEALTH EFFECTS.....	10
2.3 MINIMAL RISK LEVELS (MRLs)	12
3. HEALTH EFFECTS.....	19
3.1 INTRODUCTION.....	19
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	19
3.2.1 Inhalation Exposure	21
3.2.1.1 Death.....	21
3.2.1.2 Systemic Effects.....	21
3.2.1.3 Immunological and Lymphoreticular Effects	25
3.2.1.4 Neurological Effects	25
3.2.1.5 Reproductive Effects.....	25
3.2.1.6 Developmental Effects.....	25
3.2.1.7 Cancer	25
3.2.2 Oral Exposure.....	27
3.2.2.1 Death.....	27
3.2.2.2 Systemic Effects.....	29
3.2.2.3 Immunological and Lymphoreticular Effects	55
3.2.2.4 Neurological Effects	57
3.2.2.5 Reproductive Effects.....	59
3.2.2.6 Developmental Effects.....	59
3.2.2.7 Cancer	61
3.2.3 Dermal Exposure.....	63
3.2.3.1 Death.....	63
3.2.3.2 Systemic Effects.....	63
3.2.3.3 Immunological and Lymphoreticular Effects	66
3.2.3.4 Neurological Effects	66
3.2.3.5 Reproductive Effects.....	67
3.2.3.6 Developmental Effects.....	67
3.2.3.7 Cancer	67
3.3 GENOTOXICITY	67
3.4 TOXICOKINETICS.....	71
3.4.1 Absorption.....	71
3.4.1.1 Inhalation Exposure	71

3.4.1.2	Oral Exposure	72
3.4.1.3	Dermal Exposure	72
3.4.2	Distribution	73
3.4.2.1	Inhalation Exposure	73
3.4.2.2	Oral Exposure	73
3.4.2.3	Dermal Exposure	77
3.4.2.4	Other Routes of Exposure	77
3.4.3	Metabolism	78
3.4.4	Elimination and Excretion	82
3.4.4.1	Inhalation Exposure	82
3.4.4.2	Oral Exposure	82
3.4.4.3	Dermal Exposure	85
3.4.4.4	Other Routes of Exposure	87
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	87
3.5	MECHANISMS OF ACTION	89
3.5.1	Pharmacokinetic Mechanisms	89
3.5.2	Mechanisms of Toxicity	91
3.5.3	Animal-to-Human Extrapolations	93
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	94
3.7	CHILDREN'S SUSCEPTIBILITY	95
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	98
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Toxaphene	99
3.8.2	Biomarkers Used to Characterize Effects Caused by Toxaphene	99
3.9	INTERACTIONS WITH OTHER SUBSTANCES	99
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	100
3.11	METHODS FOR REDUCING TOXIC EFFECTS	103
3.11.1	Reducing Peak Absorption Following Exposure	103
3.11.2	Reducing Body Burden	104
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	104
3.12	ADEQUACY OF THE DATABASE	105
3.12.1	Existing Information on Health Effects of Toxaphene	105
3.12.2	Identification of Data Needs	107
3.12.3	Ongoing Studies	114
4.	CHEMICAL AND PHYSICAL INFORMATION	115
4.1	CHEMICAL IDENTITY	115
4.2	PHYSICAL AND CHEMICAL PROPERTIES	115
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	119
5.1	PRODUCTION	119
5.2	IMPORT/EXPORT	120
5.3	USE	122
5.4	DISPOSAL	123
6.	POTENTIAL FOR HUMAN EXPOSURE	125
6.1	OVERVIEW	125
6.2	RELEASES TO THE ENVIRONMENT	127
6.2.1	Air	128
6.2.2	Water	130
6.2.3	Soil	131
6.3	ENVIRONMENTAL FATE	132

6.3.1	Transport and Partitioning.....	132
6.3.2	Transformation and Degradation	140
6.3.2.1	Air	141
6.3.2.2	Water.....	141
6.3.2.3	Sediment and Soil	143
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	145
6.4.1	Air	146
6.4.2	Water.....	148
6.4.3	Sediment and Soil	150
6.4.4	Other Environmental Media.....	153
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	161
6.6	EXPOSURES OF CHILDREN	163
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	165
6.8	ADEQUACY OF THE DATABASE	166
6.8.1	Identification of Data Needs	166
6.8.2	Ongoing Studies	171
7.	ANALYTICAL METHODS.....	173
7.1	BIOLOGICAL MATERIALS	173
7.2	ENVIRONMENTAL SAMPLES	178
7.3	ADEQUACY OF THE DATABASE	189
7.3.1	Identification of Data Needs	189
7.3.2	Ongoing Studies	191
8.	REGULATIONS, ADVISORIES, AND GUIDELINES.....	193
9.	REFERENCES	199
10.	GLOSSARY	235
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE.....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1
D.	INDEX	D-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to Toxaphene - Inhalation	24
3-2. Levels of Significant Exposure to Toxaphene - Oral	45
3-3. Proposed Metabolic Scheme for a Toxicant Isolated from Toxaphene.....	79
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance.....	90
3-5. Existing Information on Health Effects of Toxaphene.....	106
4-1. Representative Carbon Skeleton Structures of the Toxaphene Congeners with Numbered Carbon Atoms	118
6-1. Frequency of NPL Sites with Toxaphene Contamination	126

This page is intentionally blank.

LIST OF TABLES

3-1. Levels of Significant Exposure to Toxaphene - Inhalation	23
3-2. Levels of Significant Exposure to Toxaphene - Oral	30
3-3. Levels of Significant Exposure to Toxaphene - Dermal.....	64
3-4. Genotoxicity of Toxaphene <i>In Vivo</i>	68
3-5. Genotoxicity of Toxaphene <i>In Vitro</i>	70
3-6. Mean Toxaphene Residues in Cows Following Oral Exposure to Toxaphene	76
3-7. Summary of Excretion Data: Percentage of Dose Excreted in Urine and Feces Following Oral Administration to Rats of Radiolabeled Toxaphene and its Components.....	83
3-8. Toxaphene Levels in Milk from Cows Fed Toxaphene in Their Diet.....	86
4-1. Chemical Identity of Toxaphene	116
4-2. Physical and Chemical Properties of Toxaphene	117
5-1. Facilities that Produce, Process, or Use Toxaphene	121
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Toxaphene.....	129
6-2. Food Web Total Toxaphene Concentrations ($\mu\text{g/g}$ Wet Weight) Measured in Lake Superior, Lake Huron, Lake Erie, and Lake Ontario	139
6-3. Names and Parlar Identification Numbers of Some Toxaphene Congeners Reported in the Literature	142
7-1. Analytical Methods for Determining Toxaphene in Biological Samples.....	174
7-2. Analytical Methods for Determining Toxaphene in Environmental Samples.....	179
8-1. Regulations, Advisories, and Guidelines Applicable to Toxaphene.....	195